Interaction between DM and TB exacerbates disease progression

Public Health Challenges and Epidemiology: Tuberculosis (TB) presents varying challenges across economic contexts. Rapid diagnosis and treatment are essential in regions with high TB prevalence to manage and prevent the disease, primarily through addressing the reactivation of latent TB infections (LTBI). In areas with lower incidence, TB tends to concentrate within high-risk groups, necessitating strategies tailored to local epidemiological patterns and social determinants. Additionally, understanding the demographic shifts towards older populations and the impact of diabetes mellitus (DM) on TB, including increased risk and poorer outcomes, is crucial.

Impact of Diabetes on Tuberculosis: Diabetes significantly increases the risk of developing active TB and affects treatment outcomes. The interaction between DM and TB exacerbates disease progression, with DM patients experiencing higher mycobacterial loads and unique lung lesions. This underscores the importance of integrated health strategies that simultaneously address both TB and DM, including enhanced screening and research into the transmission dynamics among these patients.

Study Insights and Special Populations:

• A study in metro Atlanta, Georgia (2016-2019) on HIV-negative adults with type 2 diabetes (T2DM) highlighted that LTBI was less prevalent in diabetic patients compared to controls. This suggests unique interplays between T2DM and LTBI, impacting screening and management approaches.
• The WHO emphasizes LTBI screening in populations with compromised immune systems, such as those undergoing dialysis or with chronic kidney disease (CKD), due to elevated TB risk.

Health Outcomes and Quality of Life in TB Survivors: TB survivors face considerable health challenges, including increased risks of TB recurrence and mortality. Chronic conditions such as respiratory diseases and cardiovascular issues are more prevalent among these individuals, leading to diminished quality of life and increased healthcare needs. Social and economic repercussions include stigma and financial hardship, emphasizing the need for comprehensive healthcare strategies that integrate TB care with broader health services to manage ongoing issues and improve life quality.

Epidemiological and Clinical Integration: The convergence of TB and DM epidemics, especially in regions like South-East Asia, the Western Pacific, and the Middle East, driven by rising rates of diabetes due to obesity and aging populations, calls for integrated public health responses. These should consider the compounded effects of both diseases on mortality, treatment failure, and relapse rates.

Advancements in Screening and Treatment: Advancements in technology and healthcare strategies, such as single-cell analysis and predictive modeling, hold promise for enhancing the understanding and management of TB-DM comorbidity. These tools can help in identifying new therapeutic targets and biomarkers, improving the precision of diagnostics and treatments.

Comprehensive Care for TB Survivors: Addressing the long-term health effects faced by TB survivors requires a multifaceted approach that includes lung function evaluations, pulmonary rehabilitation, and cardiovascular care. Economic support and social integration programs are also vital to mitigate the socio-economic impacts of TB on survivors and their families.

References:

1. Lee, P.H., Fu, H., Lee, M.R., Magee, M. and Lin, H.H., 2018. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. The International Journal of Tuberculosis and Lung Disease, 22(1), pp.7-16.
2. Salindri, A.D., Haw, J.S., Amere, G.A., Alese, J.T., Umpierrez, G.E. and Magee, M.J., 2021. Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta. BMC Research Notes, 14(1), p.252.
3. Zhang, X., Chen, P. and Xu, G., 2022. Update of the mechanism and characteristics of tuberculosis in chronic kidney disease. Wiener klinische Wochenschrift, 134(13), pp.501-510.
4. Kaur, R., Egli, T., Paynter, J., Murphy, R., Perumal, L., Lee, A., Harrison, A., Christmas, T., Lewis, C. and Nisbet, M., 2023. Tuberculosis and diabetes: increased hospitalisations and mortality associated with renal impairment. Internal Medicine Journal, 53(9), pp.1588-1594.
5. Choi, H., Han, K., Jung, J.H., Park, S.H., Kim, S.H., Kang, H.K., Sohn, J.W., Shin, D.W. and Lee, H., 2023. Long-term mortality of tuberculosis survivors in Korea: a population-based longitudinal study. Clinical Infectious Diseases, 76(3), pp.e973-e981. See also: https://tbreadingnotes.blogspot.com/2024/07/non-communicable-diseases-in-tb.html
6. Dodd, P.J., Yuen, C.M., Jayasooriya, S.M., van der Zalm, M.M. and Seddon, J.A., 2021. Quantifying the global number of tuberculosis survivors: a modelling study. The Lancet Infectious Diseases, 21(7), pp.984-992.

TBC 033